Patent application number | Description | Published |
20090022728 | METHODS OF TREATING OPHTHALMIC DISEASES - Methods of using inhibitors (including monoclonal antibodies) directed against amyloid-beta peptide for the treatment of ophthalmic diseases such as age-related macular degeneration are described. | 01-22-2009 |
20090291897 | METHODS FOR TREATING UNWANTED WEIGHT LOSS OR EATING DISORDERS BY ADMINISTERING A TRKB AGONIST - This invention relates to methods for treating unwanted body weight loss (such as cachexia), eating disorders (such as anorexia nervosa), or opioid-induced emesis by peripheral administration of a trkB agonist. The invention also relates to compositions and kits comprising a trkB agonist. | 11-26-2009 |
20100086997 | TrkB Agonists for Treating Autoimmune Disorders - Tyrosine receptor kinase (TrkB) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. TrkB agonists include naturally-occurring agonists, such as NT4 and BDNF, as well as agonists such as agonist antibodies. | 04-08-2010 |
20100196390 | AGONIST ANTI-TRKB MONOCLONAL ANTIBODIES - The present invention provides TrkB agonist antibodies. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to improve nerve function, including treatment of peripheral neuropathies, such as Charcot-Marie-Tooth disease. | 08-05-2010 |
20110206698 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 08-25-2011 |
20120148586 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS - Glucagon-like peptide-1 receptor (GLP-1R) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. GLP-1R agonists include, e.g., naturally-occurring agonists, such as exendin-4, as well as GLP-1R agonist peptides linked to antibodies. | 06-14-2012 |
20130028916 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 01-31-2013 |
20140141018 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 05-22-2014 |
20140335091 | ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome. | 11-13-2014 |
20140356359 | HUMAN GROWTH HORMONE RECEPTOR ANTAGONIST ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides antagonizing antibodies that bind to growth hormone receptor (GHR). The invention further relates to therapeutic methods for use of these antibodies to reduce IGF-1 levels and/or for the treatment and/or prevention of diseases associated with excessive IGF-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis, and lung inflammation. | 12-04-2014 |